What do systematic reviews say?

Intravenous iron vs placebo

• Intravenous iron therapy for non‐anaemic, iron‐deficient adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 344 participants
  Very low

Amifostine (intravenous) vs Amifostine (subcutaneous)

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

• Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

The review found no eligible studies for this question.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  No studies reported this outcome (planned secondary outcome not measured by any study in the review)
  0 studies
  No studies found

Intravenous iron vs oral iron

The review found no eligible studies for this question.

• Iron therapy for preoperative anaemia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic aciclovir (oral or intravenous) vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
  0 studies
  No studies found

Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion

• Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Intravenous thyrotropin releasing hormone vs placebo

The review found no eligible studies for this question.

• Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Reslizumab intravenous (IV) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1164 participants
  High

Reslizumab intravenous (IV) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1652 participants
  High

Mepolizumab intravenous (IV) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 369 participants
  High

Mepolizumab intravenous (IV) vs placebo

• Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 369 participants
  High

Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo

• Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 136 participants
  Very low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  GRADE not reported

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single vs combination IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulised antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab vs intravenous methylprednisolone

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low